# Pfizer Inc. – Consensus ‘buy’ rating and 16.9% Upside Potential

- Link: https://www.directorstalkinterviews.com/pfizer-inc-consensus-buy-rating-and-16-9-upside-potential/4121185458
- Published: 2025-01-31T12:17:11+00:00
- Author: Charlotte Edwards

**Pfizer Inc.** with ticker code (PFE) now have 22 market analysts covering the 
stock. The analyst consensus now points to a rating of ‘buy’. The target price High/
Low ranges between $42.00 and $25.00 with the average target price sitting at $31.13.
Given that the stocks previous close was at $26.62 this now indicates there is a
potential upside of 16.9%. The 50 day moving average now sits at $26.08 while the
200 day moving average is $27.87. The market capitalization for the company is 152.50B.
The price for the stock stands currently at: $26.91 USD

 The potential market cap would be $178,332,679,021 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 35.88, revenue per share of $10.49
and a 3.31% return on assets.

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged
in the discovery, development, manufacture, marketing, sale and distribution of 
biopharmaceutical products around the world. The Company operates through two segments:
Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business.
PC1 is its global contract development and manufacturing organization and supplier
of specialty active pharmaceutical ingredients. The Company’s primary care products
include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, 
Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty
care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra,
Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin,
and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products
include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.

Share on:
